OncoMatch/Clinical Trials/NCT06422403
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Is NCT06422403 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for carcinoma, hepatocellular.
Treatment: Extended Dosing Interval - A · Extended Dosing Interval - B · Extended Dosing Interval - C · Standard of Care - A · Standard of Care - B · Standard of Care - C — This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab, atezolizumab or pembrolizumab in advanced/unresectable gastric/gastroesophageal junction/oesphageal adenocarcinomas with PDL1 CPS ≥5%, hepatocellular carcinoma andnon-small cell lung cancer with PDL1 TPS≥50% with no prior treatment. The investigators hypothesize that nivolumab, pembrolizumab and atezolizumab can be used efficiently at extended dosing intervals, compared to their approved labels with comparable clinical outcome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Gastric Cancer
Esophageal Carcinoma
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
HER2 -ve
Required: PD-L1 (CD274) CPS ≥5% (CPS ≥5%)
PDL1 CPS ≥5%
Required: PD-L1 (CD274) TPS ≥50% (TPS ≥50%)
PDL1 TPS≥50%
Required: EGFR wild-type
EGFR/ALK wildtype
Required: ALK wild-type
EGFR/ALK wildtype
Disease stage
Required: Stage III, IV
Previously untreated locally advanced/metastatic ... not amenable to curative surgery or radiotherapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy.
Lab requirements
Blood counts
Haemoglobin ≥ 8.0 g/dL and no blood transfusions in the 28 days prior to entry; Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L; No features suggestive of MDS/AML on peripheral blood smear; White blood cells (WBC) > 3x10^9/L; Platelet count ≥ 100 x 10^9/L
Kidney function
Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN)
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN
Normal organ and bone marrow function measured within 28 days before the study as defined below: ... (see details above)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify